Cantor Fitzgerald Analysts Give Kindred Biosciences (KIN) a $25.00 Price Target

Cantor Fitzgerald set a $25.00 price objective on Kindred Biosciences (NASDAQ:KIN) in a research note published on Monday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on KIN. HC Wainwright restated a buy rating and issued a $16.00 price target on shares of Kindred Biosciences in a report on Monday, August 13th. LADENBURG THALM/SH SH downgraded Kindred Biosciences from a buy rating to a neutral rating in a report on Tuesday, August 7th. Zacks Investment Research downgraded Kindred Biosciences from a hold rating to a sell rating in a report on Tuesday, November 13th. BidaskClub downgraded Kindred Biosciences from a strong-buy rating to a buy rating in a report on Tuesday, September 11th. Finally, B. Riley increased their price target on Kindred Biosciences from $16.00 to $21.00 and gave the stock a buy rating in a report on Thursday, November 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $19.35.

NASDAQ KIN opened at $12.55 on Monday. The stock has a market capitalization of $425.61 million, a P/E ratio of -10.20 and a beta of 0.23. Kindred Biosciences has a 12 month low of $7.45 and a 12 month high of $15.75.

Kindred Biosciences (NASDAQ:KIN) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The company had revenue of $0.64 million during the quarter. On average, equities analysts expect that Kindred Biosciences will post -1.59 EPS for the current fiscal year.

In other news, CEO Richard Chin sold 40,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $14.68, for a total transaction of $587,200.00. Following the completion of the transaction, the chief executive officer now directly owns 1,986,071 shares of the company’s stock, valued at $29,155,522.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Raymond Townsend sold 3,000 shares of the company’s stock in a transaction dated Wednesday, September 26th. The stock was sold at an average price of $13.32, for a total value of $39,960.00. Following the transaction, the director now directly owns 27,813 shares of the company’s stock, valued at $370,469.16. The disclosure for this sale can be found here. Insiders sold 123,000 shares of company stock valued at $1,689,560 over the last 90 days. Corporate insiders own 15.96% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Kindred Biosciences by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,410,014 shares of the biopharmaceutical company’s stock worth $19,669,000 after buying an additional 80,023 shares during the period. Morgan Stanley lifted its holdings in Kindred Biosciences by 0.3% during the 3rd quarter. Morgan Stanley now owns 2,168,559 shares of the biopharmaceutical company’s stock worth $30,251,000 after buying an additional 7,438 shares during the period. B. Riley Financial Inc. lifted its holdings in Kindred Biosciences by 75.0% during the 3rd quarter. B. Riley Financial Inc. now owns 35,000 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 15,000 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in Kindred Biosciences by 20.3% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 63,918 shares of the biopharmaceutical company’s stock worth $892,000 after buying an additional 10,799 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in Kindred Biosciences by 28.6% during the 3rd quarter. Teachers Advisors LLC now owns 57,607 shares of the biopharmaceutical company’s stock worth $804,000 after buying an additional 12,810 shares during the period. 66.43% of the stock is owned by institutional investors.

About Kindred Biosciences

Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

See Also: Systematic Risk and Investors

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply